summARY Experiments were performed to evaluate five commercial kit assays used for the detection of antibodies to dsDNA. The kits were compared using a performance index score as recommended by the guidelines of the European Committee for Clinical Laboratory Standards. The highest performance score was obtained using the radioimmunoassay from Immunodiagnostic Services Ltd, with the Amersham kit second, the immunofluorescence test using Crithidia luciliae third, the Walker ELISA kit fourth, and the haemagglutination assay fifth. The results showed that none of the kits was outstanding, each appeared to detect a different anti-DNA antibody type as different results were obtained using each kit in assays ofquality control sera, linearity ofthe method, antibody detection in various patient groups, and interference by various substances.
The detection of antibodies to native DNA has become increasingly important in the evaluation of patients with systemic lupus erythematosus (SLE) ' and has recently been included in the revised diagnostic criteria ofthe American Rheumatism Association. 2 Most clinical laboratories in the United Kingdom now measure these antibodies by means of commercially available kits rather than by in-house methods (personal communication, UK External Quality Assurance Scheme for autoimmune serology and special immunochemistry). Commercial laboratory assays are evaluated by their manufacturers but the results of laboratory precision and accuracy as determined by the manufacturer may not be reproducible in the routine laboratory.
We selected five kit assays which utilise the most common methods used for the detection of antibodies to dsDNA and evaluated them using the recommendations of the European Committee for Clinical Labortory Standards (ECCLS).3 This committee suggests the creation of a list of performance characteristics considered to be important for an individual laboratory. Each characteristic is given a weighting factor in line with its relative importance as judged by each laboratory and then scored according to the acceptability of the results. Thus a performance index score is obtained for each kit. We assessed two Accepted for publication 2 June 1988 radioimmunoassay kits, one enzyme linked immunosorbent assay (ELISA), one passive haemagglutination assay and one indirect immunofluorescence assay. We present our interpretation of the ECCLS guidelines for the laboratory evaluation of these commercially available kits for the detection of antibodies to dsDNA.
Material and methods
The patients studied included 45 with severe SLE, most ofwhom had renal disease, who also satisfied the diagnostic criteria of the American Rheumatism Association,2 41 with seropositive rheumatoid arthritis (RA), and 120 blood donors. Clotted blood samples were obtained from all of them and the sera aliquoted and stored at -70°C until testing.
COMMERCIAL KITS
Anti-dsDNA commercial kits were obtained and used before expiry date. The manufacturers' instructions for each kit were followed. Anti Before the evaluation was started several trial runs were performed using each kit to familiarise the operator with the technique, equipment, and to resolve any difficulties encountered when running the assays.
QUALITY CONTROL SAMPLES
As some analytes in quality control materials may behave differently from those in specimens from patients a variety of quality control material was tested. For this study it was decided to use the quality control sera from IDS as they were available freeze dried and at low, medium, and high concentrations. The following freeze dried quality control samples were used: (i) the World Health Organisation (WHO), first international standard for anti-dsDNA (Wo/80) at a concentration of 200 IU/ml; (ii) Centers for Disease Control (CDC), reference serum for human antibodies to native DNA at a concentration of 0 59 pg DNA binding capacity ml; and (iii) sera which contained low, medium, and high dsDNA binding capacity (Immunodiagnostics Services Ltd, Gamma B triple check anti-dsDNA control sera). When the specified amount of distilled water was added to these samples they were regarded as neat sera.
INTERPRETATION OF RESULTS: USE OF PERFORMANCE INDEX
Experiments were performed using each kit to determine the characteristics shown below. As various laboratories may have differing views on the relative importance of the performance characteristics, each was assigned a weighting factor from 0-4; 0 being unimportant, 4 being essential. Each characteristic was also given a score on the basis of experimental result; 0 being an unacceptable result, 2 being fully acceptable. In certain circumstances a negative score was given when an exceptionally inadequate performance was found. The sum of the product of the score and weighting factor for each characteristic gave the "performance index" for each kit. The performance index values were then compared.
Evaluation offive commercial kits to detect dsDNA antibodies
The following characteristics were thought to be important for the evaluation of the kits: 1 Precision-within batch and between batch. (Both were given a weighting factor of 4 for the quantitative assays and a factor of 2 for the semiquantitative assays.) 2 Comparison of results using quality control sera. (weighting factor 2). 3 Dilution study, test for linearity (weighting factor 2). 4 Percentage correct using sera from patients with SLE, RA, and from blood donors (weighting factor 4 for patients with SLE and blood donors and 3 for patients with RA). 5 Interference study (weighting factor 3). 6 Subjective impression, including time to result (weighting factor 3) and technical difficulty (weighting factor 1).
PRECISION
Replicate assays were performed on seven sera (five of seven contained anti-DNA antibody activity spanning the analytical range and two of seven were from blood donors). For intrabatch analysis these sera were each assayed 18 times in the same run and the mean, within run standard deviation (SD), and the coefficient of variation (CV) were calculated. For interbatch analysis (day to day precision) the seven sera were assayed on five separate occasions using each kit. Again the mean, between run SD, and CV were calculated.
COMPARISON OF RESULTS USING QUALITY CONTROL SERA
The WHO quality control serum WO/80 was first used to recalibrate all the reference standards from the kits into IU/ml. In the Crithidia test the WHO serum was used directly to standardise the assay. The anti-DNA antibody activities (in IU/ml) in three quality control sera (Gamma B triple check, IDS Ltd) were then measured using the five assays. These values were then compared with the "target value" converted to IU/ml as recommended by the manufacturer. Other quality control sera were also used. As most of these were prediluted or needed to be diluted in a specific diluent before use, however, the results shown are for the IDS samples.
DILUTION STUDIES
As it is difficult to obtain sufficient quantitities of quality control sera, patient serum samples which gave similar values to the WHO quality control sera when assayed using the quantitative kits were used for this study. Nine sera were diluted in the appropriate diluent as specified by the manufacturer. Dilutions of 5:6, 4:6, 3:6, 2:6 and 1:6 of the undiluted samples were made. All the samples, including the undiluted sample, were analysed in duplicate. The undiluted sample was regarded as the true value and after correction for the dilution the percentage recovery was calculated from this value.
PATIENTS WITH KNOWN DIAGNOSIS
The anti-ds DNA activity present in the sera of 45 patients with severe SLE, 41 patients with seropositive RA, and 120 blood donors was determined using each of the five commercial kits. The sera were scored positive or negative according to the manufacturer's normal range. For Amersham International this was 0-25 U/ml, for Immunodiagnostics 0-5 mg DNA binding capacity/l, for Walker 0-42 IU/ml. For the haemagglutination and Crithidia immunofluorescence assays positivity was taken if a result at a titre of 10 or over occurred.
INTERFERENCE STUDIES
Three different substances were added to sera exhibiting a range of anti-DNA antibody activity; the specimens were then assayed using the commercial kits and the per cent increase or decrease calculated. The substances used were: dsDNA at a concentration of 100.ug/ml in PBS, ssDNA at a concentration of 100 pg/ml PBS (ssDNA was obtained by boiling then freezing the dsDNA solution five times), and histones at a concentration of 25 mg/l. All samples were incubated for two hours at room temperature, centrifuged and the supernatant assayed.
SUBJECTIVE IMPRESSION
During each evaluation the average time from starting the assay until the final result was determined; a note was also made of the operator's impression ofeach kit which included any difficulties encountered and any desirable features. The price for each test was also calculated for each assay kit. This price was calculated for running the tests in batches and included the incorporation of quality control sera in each batch.
Results

PRECISION
In this study we took the CV for RIA and ELISA to be below 15% and for other assays below 10%. A weighting factor of 4 for the quantitative assays and 2 for the semiquantitative assays was given to both the intra-and interrun assay CV. Our scoring was as follows: for the quantitative assays a CV of 0-10% obtained maximum points-2, a CV of 10-15% 1 point, and a CV ofgreater than 15% no points. For the semiquantitative assays a CV of0-5% scored 2 points, 5-10% 1 point, and over 10% no points. As the intrarun CV for all five kits was acceptable they were such a low percentage positivity with the SLE group it was given a score of -2.
INTERFERENCE STUDY
The addition of dsDNA to sera considerably reduced the antibody activity measured by all the kits with the exception of the Walker kit in which the activity was only reduced by 37% ( 
Discussion
In this study we determined a performance index score for each of five assays for antibodies to dsDNA, according to the criteria suggested by the ECCLS. The highest score was obtained by the kit produced by IDS and the lowest from the kit using the haemagglutination technique. The main reasons why the IDS kit obtained the highest mark were its precision, linearity, sensitivity and specificity for patients with SLE, McMillan, Fay together with its practicability, although it was not the cheapest test for each sample. Of all the kit assays, none scored very high marks in the evaluation when the percentge oftotal marks available was determined. Although the two semiquantitative assays scored slightly higher than half the total marks, they did receive a similar percentage of total marks as the Walker kit. It is probably unfair however, to compare these directly with the other quantitative assays. A major problem with an evaluation of this type is the lack of a plentiful supply of a universal control serum, one that contains dsDNA antibody which is revelant to disease activity. We used control sera from IDS in this study as it was available freeze dried and at three different concentrations but we accept that this choice may have slightly influenced some ofour results in favour of the IDS kit. Antibodies to dsDNA are difficult to study and interpret, mainly because of the complexity of the autoimmune response and the unique molecular features of DNA.6 It has been suggested that the sera of patients with SLE contain different populations of antibody in respect to avidity, immunoglobulin class, and antigen specificity. Each of the various methods of detection of these antibodies tends to favour one particular population. The Farr technique measures mostly high avidity antibody; the ELISA technique also measures low avidity antibody. The isotopic methods mostly measure IgG antibody, the ELISA and immunofluorescence methods can measure antibodies of different isotypes. 78 The different methods use different antigens: dsDNA, native DNA, liquid and solid phase antigen. Antibodies to a variety of DNA antigens including dsDNA, native DNA, and ssDNA are found in serum from patients with SLE.6 These different antibody populations may be reflected in the differing performance characteristics of each of the five assays used. The question is which is the best antibody population to measure in relation to disease activity? There is a debate as to which antibody population is the most relevant clinically. Various authors have examined the association between the assay result obtained using a variety ofdifferent methods and the clinical activity of disease.59`From our information on the accuracy or lack of it of these five commercial kits, it would suggest that the correlations with clinical activity may not be totally meaningful.
Another problem is determining the important experiments for the evaluation of such assays, as different laboratories may have different views on the relative importance of the performance characteristics. This has been largely overcome by the use of the performance index scoring system. It would be of considerable value to establish an agreed uniform list ofexperimental characteristics, weighting factors, and acceptance levels when doing interlaboratory studies. At the time of writing we are still waiting for a definitive test for antibodies to dsDNA, one that is precise, accurate, detects only clinically relevant antibodies to dsDNA, is not inhibited by other constituents and will differentiate patients with SLE from those with similar conditions.
